1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar
|
2
|
Hurwitz H, Fehrenbacher L, Novotny W, et
al: Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
3
|
Giantonio BJ, Catalano PJ, Meropol NJ, et
al: Bevacizumab in combination with oxaliplatin, fluorouracil, and
leucovorin (FOLFOX4) for previously treated metastatic colorectal
cancer: results from the Eastern Cooperative Oncology Group Study
E3200. J Clin Oncol. 25:1539–1544. 2007. View Article : Google Scholar
|
4
|
Jonker DJ, O’Callaghan CJ, Karapetis CS,
et al: Cetuximab for the treatment of colorectal cancer. N Engl J
Med. 357:2040–2048. 2007. View Article : Google Scholar : PubMed/NCBI
|
5
|
Van Cutsem E, Peeters M, Siena S, et al:
Open-label phase III trial of panitumumab plus best supportive care
compared with best supportive care alone in patients with
chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol.
25:1658–1664. 2007.PubMed/NCBI
|
6
|
Sobrero AF, Maurel J, Fehrenbacher L, et
al: EPIC: phase III trial of cetuximab plus irinotecan after
fluoropyrimidine and oxaliplatin failure in patients with
metastatic colorectal cancer. J Clin Oncol. 26:2311–2319. 2008.
View Article : Google Scholar : PubMed/NCBI
|
7
|
Peeters M, Price TJ, Cervantes A, et al:
Randomized phase III study of panitumumab with fluorouracil,
leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as
second-line treatment in patients with metastatic colorectal
cancer. J Clin Oncol. 28:4706–4713. 2010. View Article : Google Scholar
|
8
|
Heidelberger C, Parsons DG and Remy DC:
Syntheses of 5-trifluoromethyluracil and
5-trifluoromethyl-2′-deoxyuridine. J Med Chem. 7:1–5. 1964.
|
9
|
Fujiwara Y, Oki T and Heidelberger C:
Fluorinated pyrimidines. XXXVII. Effects of
5-trifluoromethyl-2′-deoxyuridine on the synthesis of
deoxyribonucleic acid of mammalian cells in culture. Mol Pharmacol.
6:273–280. 1970.PubMed/NCBI
|
10
|
Yoshino T, Mizunuma N, Yamazaki K, et al:
TAS-102 monotherapy for pretreated metastatic colorectal cancer: a
double-blind, randomised, placebo-controlled phase 2 trial. Lancet
Oncol. 13:993–1001. 2012. View Article : Google Scholar : PubMed/NCBI
|
11
|
Dexter DL, Wolberg WH, Ansfield FJ, Helson
L and Heidelberger C: The clinical pharmacology of
5-trifluoromethyl-2′-deoxyuridine. Cancer Res. 32:247–253.
1972.
|
12
|
Ansfield FJ and Ramirez G: Phase I and II
studies of 2′-deoxy-5-(trifluoromethyl)-uridine (NSC-75520). Cancer
Chemother Rep. 55:205–208. 1971.
|
13
|
Skevaki CL, Galani IE, Pararas MV,
Giannopoulou KP and Tsakris A: Treatment of viral conjunctivitis
with antiviral drugs. Drugs. 71:331–347. 2011. View Article : Google Scholar : PubMed/NCBI
|
14
|
Fukushima M, Suzuki N, Emura T, et al:
Structure and activity of specific inhibitors of thymidine
phosphorylase to potentiate the function of antitumor
2′-deoxyribonucleosides. Biochem Pharmacol. 59:1227–1236.
2000.PubMed/NCBI
|
15
|
Langenbach RJ, Danenberg PV and
Heidelberger C: Thymidylate synthetase: mechanism of inhibition by
5-fluoro-2′-deoxyuridylate. Biochem Biophys Res Commun.
48:1565–1571. 1972.PubMed/NCBI
|
16
|
Miller EM and Kinsella TJ:
Radiosensitization by fluorodeoxyuridine: effects of thymidylate
synthase inhibition and cell synchronization. Cancer Res.
52:1687–1694. 1992.PubMed/NCBI
|
17
|
Sampath D, Rao VA and Plunkett W:
Mechanisms of apoptosis induction by nucleoside analogs. Oncogene.
22:9063–9074. 2003. View Article : Google Scholar : PubMed/NCBI
|
18
|
Pettersen HS, Visnes T, Vågbø CB, et al:
UNG-initiated base excision repair is the major repair route for
5-fluorouracil in DNA, but 5-fluorouracil cytotoxicity depends
mainly on RNA incorporation. Nucleic Acids Res. 39:8430–8444. 2011.
View Article : Google Scholar : PubMed/NCBI
|
19
|
Suzuki N, Emura T and Fukushima M: Mode of
action of trifluorothymidine (TFT) against DNA replication and
repair enzymes. Int J Oncol. 39:263–270. 2011.PubMed/NCBI
|
20
|
Quesada-Soriano I, Casas-Solvas JM, Recio
E, et al: Kinetic properties and specificity of trimeric
Plasmodium falciparum and human dUTPases. Biochimie.
92:178–186. 2010. View Article : Google Scholar : PubMed/NCBI
|
21
|
Emura T, Nakagawa F, Fujioka A, et al: An
optimal dosing schedule for a novel combination antimetabolite,
TAS-102, based on its intracellular metabolism and its
incorporation into DNA. Int J Mol Med. 13:249–255. 2004.PubMed/NCBI
|
22
|
Markley JC, Chirakul P, Sologub D and
Sigurdsson ST: Incorporation of 2′-deoxy-5-(trifluoromethyl)uridine
and 5-cyano-2′-deoxyuridine into DNA. Bioorg Med Chem Lett.
11:2453–2455. 2001.
|
23
|
Bijnsdorp IV, Peters GJ, Temmink OH,
Fukushima M and Kruyt FA: Differential activation of cell death and
autophagy results in an increased cytotoxic potential for
trifluorothymidine compared to 5-fluorouracil in colon cancer
cells. Int J Cancer. 126:2457–2468. 2010.
|